https://doi.org/10.4081/monaldi.2024.3103
Clinical profile, risk factors, disease severity, and outcome for COVID-19 disease in patients with tuberculosis on treatment under the National Tuberculosis Elimination Program: a cohort of 1400 patients
Accepted: September 19, 2024
SUPPLEMENTARY MATERIAL: 3
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
COVID-19 affected millions of people worldwide, and tuberculosis (TB) continues to affect millions of people each year. The combined pandemic of COVID-19 and TB had a catastrophic effect on healthcare policies and healthcare setups around the globe. The clinical profile and factors affecting the outcome of COVID-19 disease in TB patients on treatment in field conditions have not been studied in detail. The present study attempted to study the occurrence of COVID-19 among patients on TB treatment in terms of severity of COVID-19 disease and outcome of both COVID-19 and TB in patients at National Tuberculosis Elimination Program treatment centers over a period of one year during peak COVID-19 times. Out of 1400 TB patients enrolled, 65 (5%) suffered from COVID-19 disease. Of the 65 TB patients with COVID-19 disease, 37 (57%) were male and under 45 years old, 33 (51%) had a TB diagnosis after first receiving a COVID-19 diagnosis, 29 (45%) had a TB diagnosis first, and received anti-TB treatment before receiving a COVID-19 diagnosis, and only 3 patients (5%) had a COVID-19 and TB diagnosis concurrently. The majority of 59 (91%) patients had mild COVID-19 disease. The outcome of TB treatment was available in 25 patients out of these 65 COVID-19-positive patients, with 21 (84%) patients having a favorable outcome. Out of the 65 COVID-19-positive patients, 4/25 (16%) had unfavorable outcomes, with one patient (4%) failing TB treatment and two patients (8%) dying. This is the first study from India that studied the occurrence and course of COVID-19 among a large number of TB patients taking anti-TB treatment under programmatic conditions. Due to the similarity in symptoms of TB and certain viral respiratory illnesses, a protocol should be established for health care to check patients for both illnesses.
Ethics Approval
Research and ethical approval (office letter no. NITRD/RC/2021/6291, letter no. NITRD/EC/2021/6831 respectively) were obtained from Institutional Research and Ethical Committee.How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Neeti Rustagi, Yachana Choudhary, Shahir Asfahan, Kunal Deokar, Abhishek Jaiswal, Prasanna Thirunavukkarasu, Nitesh Kumar, Pankaja Raghav, Identifying psychological antecedents and predictors of vaccine hesitancy through machine learning: A cross sectional study among chronic disease patients of deprived urban neighbourhood, India , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Saroj Kumari Meena, Rajnish Gupta, Manmohan Puri, Existence and pattern of sleep-related breathing disorders in patients diagnosed with bronchial asthma , Monaldi Archives for Chest Disease: Early Access
- Sonam Spalgais, Siddharth Raj Yadav, Parul Mrigpuri, Raj Kumar, Spirometry findings of chronic lung disease in high-altitude residents of Ladakh (>11,000 feet above sea level) , Monaldi Archives for Chest Disease: Early Access
- Diana Alexandra Gonçalves Pimenta, Renata Carvalho, Raquel Pereira, Rui Rolo, Lurdes Ferreira, Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma , Monaldi Archives for Chest Disease: Vol. 93 No. 2 (2023)
- Rozandeep Kaur, Neha Uppal, Vibha Uppal, Anju Sharma, Impaired glycemic control as a risk factor for reduced lung function in the Indian diabetic population , Monaldi Archives for Chest Disease: Early Access
- Berardo Sarubbi, Gabriella Farina, Diego Colonna, Anna Correra, Emanuele Romeo, Giovanni Domenico Ciriello, Guido Oppido, Maria Giovanna Russo, Subcutaneous finger cardioverter-defibrillator in low weight paediatric patients: a case series , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Deldar Morad Abdulah, Rasoul Sabri Piro, Pranee Liamputtong, The lived experience of hospitalized and non-hospitalized health care providers of COVID-19 pandemic: a qualitative study , Monaldi Archives for Chest Disease: Vol. 93 No. 4 (2023)
- Davorka Muršić, Tajana Jalušić Glunčić, Jelena Ostojić, Sanda Škrinjarić Cincar, Ljiljana Bulat Kardum, Martina Dokoza, Nataša Karamarković Lazarušić, Erim Bešić, Miroslav Samaržija, Andrea Vukić Dugac, Differences in nutritional status of patients with chronic obstructive pulmonary disease between Mediterranean and non-Mediterranean regions in Croatia , Monaldi Archives for Chest Disease: Early Access
- Lucrezia Piccioli, Michele Arcopinto, Andrea Salzano, Roberta D'Assante, Alessandra Schiavo, Francesca M. Stagnaro, Anna Lombardi, Veronica Panicara, Pietro Valente, Giuseppe Vitale, Filippo M. Sarullo, Francesco Giallauria, Alberto M. Marra, The impairment of the Growth Hormone/Insulin-like growth factor 1 (IGF-1) axis in heart failure: A possible target for future therapy , Monaldi Archives for Chest Disease: Vol. 88 No. 3 (2018)
- Roberto F.E. Pedretti, Beta-blockers after myocardial infarction: Are they useful to all patients? And how long should be the beta-blocker therapy? , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
<< < 28 29 30 31 32 33 34 35 36 37 > >>
You may also start an advanced similarity search for this article.
